title: Novel therapeutic options in Acute Myeloid Leukemia.
abstract: Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence is increasing as the population ages. Cytogenetic anomalies and mutation testing remain important prognostic tools for tailoring treatment after induction therapy. Despite major advances in understanding the genetic landscape of AML and its impact on the pathophysiology and biology of the disease, as well as the rapid development of new drugs, standard treatment options have not experienced major changes during the past three decades. Especially for patients with intermediate or high-risk AML, which often show relapse. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the best chance for cure. Here we review the state of the art therapy of AML, with special focus on new developments in immunotherapies and cellular therapies including HSCT and particularly discuss the impact of new conditioning and haplo-identical donor regimens for HSCT, post-transplant strategies for preventing and treating relapse, and emerging novel therapeutic options.
authors.affiliation: Divisions of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland; Divisions of Internal Medicine, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
authors.forename: Michael
authors.initials: M
authors.lastname: Medinger
authors.affiliation: Divisions of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
authors.forename: Claudia
authors.initials: C
authors.lastname: Lengerke
authors.affiliation: Divisions of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
authors.forename: Jakob
authors.initials: J
authors.lastname: Passweg
keywords: Acute myeloid leukemia; Cellular therapies; Haplo-identical; Hematopoietic stem cell transplantation; Immunotherapy; Molecular targeted therapies